Ophthotech gains commericial rights to AMD antibody

Article

Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration.

Ophthotech, Biogen and PDL BioPharma have entered into an exclusive worldwide licensing agreement for an anti-angiogenesis antibody to treat age-related macular degeneration (AMD).

Under the terms of the agreement, Biogen and PDL have granted Ophthotech worldwide development and commercial rights to all ophthalmic uses of volociximab, an investigational monoclonal antibody targeting (alpha)5(beta)1 integrin, a key protein involved in the formation of blood vessels.

Biogen and PDL will each receive an equity position in Ophthotech as well as a combination of development milestone payments and royalties on future product sales.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.